Please ensure Javascript is enabled for purposes of website accessibility

Why Canopy Growth, Aurora Cannabis, and Hexo Stocks Went Up in Smoke Today

By Rich Smith - Apr 12, 2021 at 12:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Blame Aphria.

What happened

It's Monday, and marijuana stocks are vaporizing. In 11:30 a.m. EDT trading, Canopy Growth (CGC -1.40%) stock is down a depressing 4.4%, and cannabis rivals Aurora Cannabis (ACB 2.27%) and Hexo (HEXO 0.67%) have both tumbled about 8% each.

And if you want to know why, ask Aphria (APHA).

Smoke filled room in black and white

Image source: Getty Images.

So what

Yes, unfair as it may feel, the stock to blame for Canopy's, Aurora's, and Hexo's declines today is none of the above, but rather their cannabis-growing rival Aphria, which reported its fiscal Q3 2021 earnings results this morning.

Suffice it to say that the news was not good.  

Sales at the Canadian cannabis company grew a respectable 6% to CA$153.6 million in Q3 2021, but that was well below the CA$166.2 million that analysts had predicted. Worse, Aphria reported a CA$1.14-per-share loss for the quarter, versus the tiny profit (calculated according to generally accepted accounting principles or GAAP) reported a year ago. In terms of U.S. dollars, Aphria lost $0.91 per share.

Now what

Aphria blamed "the duration and impact of lockdowns across many of the regions we operate in, particularly in Canada" for its disappointing results, but insisted that it "remains well-positioned with our leading brands and market share to experience a robust increase in our top-line as the market improves" and said it is still "excited about the strategic opportunities for incremental growth," particularly in the U.S. market.

Regardless, the fact that Aphria's gross profits on its sales declined by nearly half in the quarter suggests that demand for the product isn't necessarily Aphria's (or Canopy's or Aurora's or Hexo's) biggest problem going forward. Shrinking profit on growing sales speaks to declining pricing power in the industry as oversupply continues to weigh on profitability for medical marijuana and recreational marijuana alike.

That's not good news for Aphria's future. It's not good news for Canopy Growth, Aurora Cannabis, or Hexo, either.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$2.81 (-1.40%) $0.04
Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$1.35 (2.27%) $0.03
HEXO Stock Quote
HEXO
HEXO
$0.21 (0.67%) $0.00
Aphria Stock Quote
Aphria
APHA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.